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Abstract
The Raf/ERK (Extracellular Signal Regulated Kinase) signal transduction pathway controls numerous cellular processes,
including growth, differentiation, cellular transformation and senescence. ERK activation is thought to involve complex
spatial and temporal regulation, to achieve a high degree of specificity, though precisely how this is achieved remains to be
confirmed. We report here that prolonged activation of a conditional form of c-Raf-1 (BXB-ER) leads to profound changes in
the level and distribution of a heterochromatic histone mark. In mouse fibroblasts, the heterochromatic trimethylation of
lysine 9 in histone H3 (H3K9Me3) is normally confined to pericentromeric regions. However, following ERK activation a
genome-wide redistribution of H3K9Me3 correlates with loss of the histone modification from chromocentres and the
appearance of numerous punctuate sites throughout the interphase nucleus. These epigenetic changes during interphase
correlate with altered chromosome structure during mitosis, where robust H3K9Me3 signals appear within telomeric
heterochromatin. This pattern of heterochromatinization is distinct from previously described oncogene induced
senescence associated heterochromatin foci (SAHF), which are excluded from telomeres. The H3K9Me3 histone mark is
known to bind the major heterochromatin protein HP1 and we show that the alterations in the distribution of this histone
epistate correlate with redistribution of HP1b throughout the nucleus. Interestingly while ERK activation is fully reversible,
the observed chromatin changes induced by epigenetic modifications are not reversible once established. We describe for
the first time a link from prolonged ERK activation to stable changes in genome organization through redistribution of
heterochromatic domains involving the telomeres. These epigenetic changes provide a possible mechanism through which
prolonged activation of Raf/ERK can lead to growth arrest or the induction of differentiation, senescence and cancer.
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Introduction
Cells respond to extra-cellular cues by activating signal
transduction networks like the Raf/ERK pathway, which is
downstream of receptor tyrosine kinases. As a consequence of the
activationofgrowthfactorreceptors,Rasispresentinitsactiveform
ontheinnerplasmamembrane.Rafkinasesbind toactivated Rasas
part of their complex activation mechanism. Active Raf in turn
phosphorylates and activates MEK 1/2 (Mitogen activated Protein
Kinase-/Extracellular Signal Regulated Kinase-Kinase) which in
turn phosphorylate and activate ERK1/2 (for a recent review see
[1]). Other elements of regulation of the Ras/Raf/MEK/ERK
pathway include homo and heterodimerization of a variety of
proteins as well as both activating and inhibitory phosphorylations.
TheERK pathwayalsoshowsa varietyoffeedbackinhibitionloops,
autocrine regulation and an extensive crosstalk to other signaling
modules like PI3(Phosphoinositide 3) kinases or PKCs (Protein
Kinase C). ERKs are the workhorses of this signaling cascade and
have more than 160 cellular substrates [2].
Whilst the known ERK substrates are spread over several
cellular compartments and localizations, special attention has
historically be paid to nuclear substrates. Activated ERKs can
accumulate in the nucleus [3] where modification of transcription
factors can drive gene expression [2,4]. The cumulative phos-
phorylation of ERK substrates regulates numerous cellular events
including cell transformation and tumor development [3,5–7]. At
the moment, it is not well understood how the activation of such a
ubiquitous pathway, with a multitude of substrates, can have the
very specific cellular outcomes observed in a variety of cellular
model systems. Signal duration is one regulatory element defining
biological function [4], although how prolonged ERK activation
induces irreversible effects like senescence and differentiation (as
opposed to growth following short term activation) is not known
and a matter of controversy [8–11]. Interestingly, in PC12 cells
prolonged ERK activation, as induced by NGF (Neuronal Growth
Factor), induces differentiation, while short term ERK activation,
induced by EGF (Epidermal Growth Factor), causes growth.
Proteins preferentially interacting with ERK after NGF stimula-
tion are involved in a variety of cellular processes like signaling,
apoptosis regulation, protein transport and metabolism; just a
minor portion are transcriptional regulators [12]. This indicates
that processes outside transcriptional regulation might be impor-
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was also shown that, apart from the induction of immediate early
genes via the phosphorylation of transcription factors, ERK
activation can lead to long-term reprogramming of gene
expression through alterations in chromatin organization and
DNA methylation [4,13–15].
A preliminary proteomics study in our laboratory (unpublished)
identified several proteins involved in the regulation of chromatin
and nuclear structures as targets of Raf signaling. Amongst those
proteins were RNF2 (Ring Finger 2), nuclear lamins and HP1
(Heterochromatin Protein 1) proteins. These preliminary studies
showed that prolonged activation of Raf/ERK influenced proteins
involved with the epigenetic histone code. The interaction
between DNA, chromatin and chromatin associated factors are
very complex and regulate functions in information maintenance
and transcriptional regulation.
Epigenetic chromatin marks (mainly modifications of histone
tails) as well as the methylation state of the DNA regulate DNA
interactions with chromatin associated factors, defining chromatin
patterns that correlate with transcriptional status [16]. Different
epigenetic marks define patterns of chromatin folding that are
permissive or repressive for gene expression. The corresponding
chromatin states, euchromatin and heterochromatin, are faithfully
transmitted to daughter cells during mitosis, in order to maintain
epigenetic programming [17]. As an essential component of global
chromatin organization, pericentric heterochromatin plays a
fundamental role in both, nuclear organization and gene silencing.
It is made up of tandem repeats of a 234 bp A-T rich motif, called
the major satellite, constituting a domain which directly flanks the
inner centromere. Interestingly during interphase, pericentric
satellites from different chromosomes gather and form large
domains called chromocenters, which are particularly prominent
in murine cells. These centers display specific and robust
epigenetic marks, which are maintained through many cell cycles
[18]. In this chromatin compartment, the compact chromatin,
which is ‘glued’ by many silencing factors, creates an environment
that is highly repressive for transcription. This is evident during
cell differentiation, when inactive genes are often seen to lie in the
vicinity of heterochromatic domains [19–22]. Hence, nuclear
remodeling and chromatin dynamics are key features of cell
differentiation [23] and the organization of heterochromatic
domains contributes to this process [24].
Silencing at chromocenters can result directly from their unique
epigenetic patterns of post-translational histone modifications.
Indeed, histone methyltransferases homologous to Su(var)3–9
specifically methylate lysine 9 of histone H3 at pericentric satellites
(H3K9Me3, [25]). The a and b isoforms of HP1 also bind to the
modified histone tails and altogether these marks contribute to
maintenance and propagation of heterochromatin at chromocen-
ters [26,27]. HP1 is a 25 kDa protein, which is ubiquitous in
eukaryotes [28,29]. Three domains are responsible for the
complex functions of HP1 [26]: i) a ‘‘chromo’’ domain (for
‘chromatin-organization modifier’) which recognizes the
H3K9Me3 [30,31]: ii) a ‘‘hinge’’ domain that binds RNA and
DNA [32,33] and iii) a ‘‘chromoshadow’’ domain, which facilitates
HP1 dimerization and thereby heterochromatin propagation. In
D. melanogaster HP1 is known to be a key determinant of gene
silencing in the vicinity of heterochromatin blocks [34] and the
protein is thought to play a similar role in mammalian cells.
Following our preliminary observations, the aim of this study
was to evaluate if Raf/ERK activation can alter global nuclear
organization, particularly the structure of major chromatin
compartments in mouse fibroblasts, using a conditional form of
Raf, BXB-ER [35]. BXB-ER is a fusion protein of the human
estrogen receptor hormone binding region and the carboxy-
terminal half (containing the kinase domain) of human c-Raf-1,
which is only active in the presence of estrogen. Taking advantage
of the targeted activation of the BXB-ER activity, we observed
that activation of Raf resulted in profound changes in the
distribution of heterochromatin, which was seen to spread to sites
throughout the genome and notably at telomeres. The re-
organization of the heterochromatin specific epigenetic marker
H3K9Me3 was mimicked by changes in the distribution of the
heterochromatin binding protein HP1. Moreover, the nuclear
changes seen during Raf/ERK activation were shown to correlate
with alterations in cell cycle progression and the onset of p21
induced cell cycle arrest. This implies that changes in the
organization of heterochromatin contribute to the cell cycle arrest
that is induced by prolonged activation of the Raf/ERK pathway.
Results
Control experiments were performed to ensure that BXB-ER
does indeed activate MEK which then results in activation of
ERK1/2 in our system just as shown before [35]. We also wanted
to control that the estrogen used for activating the kinase activity
of BXB-ER has no effect on ERK activity in 3T3 cells. For this,
3T3 control cells and 3T3BXB-ER cells were treated for 7 and
15 hours with estrogen and ERK1/2, activated by phosphoryla-
tion on residues Thr 202 and Tyr 204, was detected by Western
blot (Fig. 1A). There was a small amount of activated ERK1/2 in
untreated 3T3 cells and this was not influenced by estrogen
treatment. When cells were treated with 2 different inhibitors of
the Raf and BXB-ER mediated MEK activation, PD09859 and
UO-126 [36,37], the endogenous level of ERK1/2 activity was
suppressed completely. Similar to 3T3 cells, 3T3BXB-ER cells
also showed a small amount of phosphorylated ERK1/2 in the
absence of estrogen. However, in contrast to the situation in 3T3
cells, 3T3BXB-ER cells expressing BXB-ER showed enhanced
ERK1/2 activity after 7 hours of estrogen treatment and ERK1/2
activity was further increased after 15 hours of estrogen treatment.
Analysis of total ERK1/2 amounts by Western blot showed that
the regulation of ERK1/2 activity is mainly on the level of protein
phosphorylation, as no global changes in the abundance of
ERK1/2 were seen under any of the treatment condition (Fig. 1A).
Nuclear structure and distribution of heterochromatin in
3T3BXB-ER cells and in control 3T3 cells were monitored by
DNA staining (Fig. 1B). 3T3 cells, 3T3 cells treated with estrogen
and untreated 3T3BXB-ER cells displayed classical chromatin
organization with dispersed euchromatin punctuated by a small
number of discrete brightly-stained clumps of heterochromatic
chromocenters and some small dense chromatin clumps along the
nuclear periphery and around nucleoli (Fig. 1B). Cells with
activated BXB-ER (and thus activated MEK/ERK Fig. 1A and
[35]) displayed a heterogeneous texture with more dense
chromatin aggregates (Fig. 1B, arrows) and discrete chromatin
foci along the nucleolar periphery and nuclear lamina (Fig. 1B,
arrowheads). Quantification of several hundred nuclei showed that
this phenotype is predominant in activated BXB-ER nuclei and
essentially absent in the nuclei of control cells including 3T3 cells
treated with estrogen (Fig. 1C). 3T3BXB-ER cells show minor
changes in the structure of heterochromatin when compared with
3T3 control cells, consistent with a slight ‘‘leakiness’’ of the
conditional Raf, which was also observed in previous studies [35].
The chromatin changes we observed following BXBER activa-
tion correlated with an overall decrease in nuclear diameter in
3T3BXB-ER cells after 15 hours of BXB-ER activation (Fig. 1D/
E). Measuring the nuclear diameters from 100 cells for each sample,
Raf/ERK Targets Hetrochromatin
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for cells treated with ethanol (carrier for estrogen) alone and
16.57+/22.08 mm after 15 hours of estrogen treatment. The nuclei
of BXB-ER cells on the other hand were measured at
14.09+/21.52 mm and at 11.76+/21.55 mm for ethanol/estrogen
treated cells respectively. The differences between the values from
the 3T3BXB-ER cells as well as the differences between 3T3 and
3T3BXB-ER cells were highly significant (p#0.001), resulting in a
decreased nuclear volume by ,40% in estrogen treated BXB-ER
cells. Measurements of the size distribution of the nuclei from 3T3
and 3T3BXB-ER cells after estrogen treatment (Fig. 1E) showed
that changes in cell cycle distribution can not be a major
contributing factor for the reduced nuclear diameter in 3T3BXB-
ER cells after estrogen treatment, as the peak value of nuclear
diameters of estrogen treated BXB-ER cells is completely outside
the range of nuclear size distribution in 3T3 cells. We conclude that
activated BXB-ER (and thus prolonged ERK activation) leads to a
significant decrease in nuclear size in 3T3BXB-ER cells, which is
not directly linked to their cell cycle distribution. Untreated
3T3BXB-ER cells also have a slight decrease in nuclear size
compared to 3T3 cells. This partial phenotype is consistent with
some leakiness of the BXB-ER construct (see also [35]).
As changes in nuclear volume often correlate with alteration in
functional status, we monitored the distribution of fibrillarin
in nucleoli. Fibrillarin is a marker for active transcription centers
in nucleoli and stains coiled bodies, which show as bright single
spots, providing a marker for global nucleolar organization and
transcriptional activity [38]. BXB-ER activation had no effect on
the number or structure of nucleoli or their active centers (Fig. 1D).
Thus, the reduced nuclear volume in cells with activated BXB-ER
correlated with global condensation of heterochromatin and
genome compaction, even though the transcriptional status of
nucleoli is unaltered. Interestingly, a previous study [35] showed
that BXB-ER activation also induces bundling of the cytoskeletal
microtubules and an elongated cell shape. These microtubular
changes correlate with changes of the cell shape; the predomi-
nantly flat 3T3 BXB-ER cells become more elongated and
develop a spindle-shaped morphology after estrogen treatment,
while 3T3 show no changes after estrogen treatment [35]. We
have no indication that these morphological changes in 3T3BXB-
ER result in changes of cellular volume, as we never observed a
change in the volumes of cellular pellets after estrogen treatment
(data not shown). Also the fresh weight of cellular pellets does not
show any statistically significant differences after estrogen
treatment, with average values of 31.1 +/2 5.7 pg/cell for control
3T3 cells and 46.6 +/2 19.2 pg/cell for estrogen treated 3T3
cells. The values for control and estrogen treated 3T3BXB-ER
cells were 38.5 +/2 22 pg/cell and 28.0 +/2 9.5 pg/cell
respectively (see Material and Methods). In summary whilst we
can not exclude minor changes in cellular volumes during our
experiments, the dramatic changes in nuclear volume after BXB-
ER activation are not accompanied by obvious changes in the
overall volumes of the cells.
To characterize potential chromatin rearrangements following
BXB-ER activation we analyzed the distribution of epigenetic
markers associated with pericentric heterochromatin using anti-
bodies to the heterochromatic histone modification H3K9Me3. In
the acrocentric mouse chromosomes, pericentric heterochromatin
is also sub-telomeric. The pericentric heterochromatin aggregates
into ,10 chromocenters per nucleus, which are known to be very
prominent in murine cells [27,39]. Immunostaining of 3T3 cells
and untreated 3T3BXB-ER showed that H3K9Me3 was restricted
to the heterochromatin within chromocentres (Fig. 2A). In
addition, chromocentres were enriched for the H3K9Me3
associated heterochromatin protein 1 b (HP1b; Fig. 2A). However,
activation of BXB-ER induced a diminished H3K9Me3 staining
at chromocentres and a dramatic increase in dispersed H3K9Me3
staining throughout the nucleus (Fig. 2A), while no changes in
H3K9Me3 staining patterns could be observed in estrogen treated
3T3 cells (Fig. 2F). Heterochromatin associated HP1b binds
strongly and specifically to H3K9Me3 [26]. We analyzed the
distribution of HP1b in control cells and cells with activated BXB-
ER (Fig. 2A). The HP1b staining pattern was almost identical to
the staining pattern of H3K9Me3. However, the phenotype of the
loss of structure for the staining pattern of heterochromatin
associated HP1 was even more pronounced than that of
H3K9Me3 in cells with activated BXB-ER, leading to some
chromocentres showing a slightly greater loss of HP1b compared
to H3K9Me3 (Fig. 2A, arrow). Changes were quantified by
scoring the distribution of patterns of H3K9Me3 staining (Fig. 2B)
and HP1b staining (Fig. 2C) at chromocentres and in the
nucleoplasm of several hundred individual cells (see Material
and Methods). 3T3 cells showed no differences in staining patterns
after estrogen treatment (Fig. 2F) and are included in the
quantification as a reference.
To assess the genome-wide location of the H3K9Me3
distribution at higher resolution, we next analyzed chromatin
distribution in mitotic cells (Figs. 2D/E). In control 3T3 cells
H3K9Me3 exclusively decorated the pericentromeric regions of
chromosomes (Fig. 2D). In untreated 3T3BXB-ER cells we
observed some minor additional sites of H3K9Me3 decoration.
However, following activation of BXB-ER an obvious increase in
staining was seen on specific locations throughout the chromo-
some arms (Fig. 2D). Notably, the altered staining pattern
decorated sub-chromosomal bands on many chromosomes
(Fig. 2D) and strongly stained telomeres, which lie distal to the
pericentromeric heterochromatin (e.g. Fig. 2D, arrowhead). 3D
reconstructions of the chromosomal structures showed the overall
spatial architecture of the chromosomes (Fig. 2E). The 3D
structures clearly showed the pericentromeric heterochromatic
patterns in normal 3T3 cells and that the normal chromosomal
architecture in metaphase cells was lost in cells with activated
Figure 1. BXB-ER activation induces chromatin rearrangement and reduced nuclear diameter. (A) Western blot of 3T3 and 3T3BXB-ER
cells for phosphorylated ERK1/2 (left panel) and for total ERK1/2 (right panel). Cells were treated with estrogen for 7 hours or 15 hours as indicated.
PD09859 and UO-126 were added either 30 sec before estrogen was added (7 h est. and 15 h est.) or 15 hours before the cells were harvested (no
est.). 20 mg of protein from the various whole cell lysates were loaded into each lane. (B) Optical sections of control 3T3 and 3T3BXB-ER cells stained
with Sytox green to show DNA distribution. Enhanced condensed chromatin clumps (arrow) and rims surrounding nucleoli and nuclear periphery
(arrowheads) after BXB-ER activation by addition of estrogen for 15 hours (*) are indicated. Scale bars: 20 mm. (C) Proportions of normal (grey) and
condensed (black) chromatin phenotypes after analysis of ,100 cells per condition. ‘‘normal’’ nuclei are defined by the absence of a nuclear rim, the
absence of rims surrounding the nucleolei and the absence of condensed nuclear clumps. ‘‘condensed’’ nuclei were defined by the presence of at
least one of these features. Nearly all condensed nuclei displayed all three features at the same time. (D) 3D reconstructions of cells
immunoprocessed for fibrillarin [38] show no changes in nucleolar structure. The dotted lines indicate the outline of nuclei. Scale bars: 10 mm. (E) Size
distribution of nuclei in untreated and estrogen treated 3T3 and 3T3BXB-ER cells. The mean diameters of 100 nuclei for each condition were
determined and sorted in 1 mm wide bins.
doi:10.1371/journal.pone.0013322.g001
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fluffy chromosome structure, so that discrete daughter chromatids
were no longer evident. The reorganization of H3K9Me3
correlated with a deterioration of chromosome organization and
orientation on the metaphase plate (Figs. 2D/E). In contrast to the
changes following the activation of BXB-ER with estrogen, no
changes at all could be detected in the H3K9Me3 staining pattern
in mitotic 3T3 cells after the treatment with estrogen (Fig. 2F).
The spreading of heterochromatic histone marks on chromo-
somes as evident from Figs. 2D/E is clearly consistent with the large
number of nucleoplasmic H3K9Me3 sites that are seen in
interphase cells following BXB-ER activation (Figs. 2A/B). To
investigate the impact of alterations in the H3K9Me3 distribution
we analyzed the HP1 proteins HP1a and HP1b, which are known
to interact with H3K9Me3 in chromatin and can have slightly
different localizations within euchromatin and heterochromatin
[26]. Western blotting revealed that expression of HP1b was
essentially unchanged following BXB-ER activation (Fig. 3A). To
establish if the association of HP1b with H3K9Me3 was affected by
BXB-ER activation we probed immunoprecipitates of H3K9Me3
for the presence of associated HP1b by Western blotting. These
experiments showed that the association of HP1b to H3K9Me3 was
unaltered in 3T3BXB-ER cells, regardless of BXB-ER activation
and was essentially the same as in 3T3 cells (Fig. 3A).
Phosphorylation of HP1 proteins dictates their role in gene
silencing [40,41] as well as their nuclear localization during the cell
cycle [42] and can influence their association with H3K9Me3
[43]. HP1b interacts in heterochromatin with other family
members, like HP1a, to regulate the structure and function of
heterochromatin [26]. We thus assessed if changes in phosphor-
ylation of HP1a or HP1b might account for the altered
localization following BXB-ER activation we observed for
HP1b. Proteomic analysis of
32P labeled phosphorylated proteins
from 2-D PAGE gels revealed a protein whose phosphorylation
was increased within 20 min of activation of BXB-ER (Fig. 3B).
This protein was identified as Hp1a using Peptide Mass
Fingerprinting (Figs. 3C/D). In contrast, Western blots of 2-D
PAGE gels showed no major changes in post-translational HP1b
isoform patterns (Fig. 3E; 6 isoforms marked). Based on its
isoelectric point and its relation to the other HP1b isoforms
detected in the Western blot, spot 1 in Figure 3E represents most
likely the unphosphorylated form of HP1b. This form had the
weakest intensity of all HP1b isoforms detected and its intensity
diminished even further after activation of BXB-ER in several
experiments. Taken together these experiments suggest that whilst
there is some increase in the phosphorylation of HP1a and HP1b
proteins following the activation of BXB-ER, the association of
HP1b with H3K9Me3 is not affected significantly (Fig. 3A). Thus
the driving force behind HP1b re-localization, is not phosphor-
ylation. Instead BXB-ER activation induced changes in repressive
H3K9Me3 chromatin marks and subsequent association of HP1b
to these new sites is sufficient to explain the observed HP1b
redistribution (Fig. 2A).
The reversibility of Raf/ERK induced chromatin remodeling
was tested in time course experiments with the MEK inhibitor
PD098059 [36]. Activation of BXB-ER in the presence of
PD098059 eliminated the characteristic changes in H3K9Me3
and HP1b organization in interphase cells (compare Fig. 4A with
Fig. 1B and Figs. 2A/D). The reversal of the effect of activated
BXB-ER by PD098059 can also be seen in mitotic cells, where
only pericentric H3K9Me3 staining on 3D reconstructed
chromosomes can be observed, similar to the staining pattern
observed in untreated 3T3 cells. Spreading of the H3K9Me3 stain
to specific site throughout the genome and especially to the
telomeres was not observed when cells with activated BXB-ER
were also treated with PD098059 (compare Fig. 2D with Fig. 4A,
panel on the right). Incubating 3T3BXB-ER with PD098059 in
the absence of BXB-ER activation eliminated any residual BXB-
ER and ERK activity (see Fig. 1A and [35]) and reverted the
distribution of H3K9Me3 to 3T3 cell control status (Figs. 4B/2A).
Following activation of BXB-ER for 15 hours, the redistribution of
H3K9Me3 spread throughout nuclei (Fig. 4C). Once established,
the structures formed by the H3K9Me3 redistribution remained
unchanged even when cells were grown in either fresh medium
without oestradiol (Fig. 4D) or with PD098059 (Fig. 4E). This is
despite the fact that PD098059 can reverse the effect of BXB-ER
activation on the activation of ERKs at any time (see Figure 1A,
and Fig. 4A). The results for 12 and 24 hours chase periods with
fresh medium or with PD098059 containing fresh medium (data
not shown) were identical to the results of the 7 hours chase
periods shown in Figs. 4D/E. This analyses show that once the
epigenetic changes to H3K9Me3 are established they remain
stable and unaffected by the BXB-ER activation status.
Prolonged activation of Raf can have various results on cells,
involving differentiation, proliferation and cell cycle arrest
[3,4,8,11]. We tested the effects of BXB-ER activation on the cell
cycle in our cellular system by FACS (Fluorescence Activated Cell
Scan) analysis of DNA incorporation and total DNA content
(Fig. 5A). While estrogen treatment of 3T3 control cells for 8 hours
has no effect on the distribution of cells in the cell cycle, the
activation of BXB-ER by estrogen in 3T3BXB-ER cells induces a
visible change within 8 hours of estrogen treatment. Fewer cells
transit from the G1-phase into the S-phase of the cell cycle at this
time point, resulting in a sparsity of cells in early S-Phase. After
24 hours of estrogen treatment the block in the cell cycle is even
more pronounced and the amount of cells in the S-phase is lowered
throughout the entire S-phase. Analysis of the numerical distribu-
tion of cells in the different stages of the cell cycle shows that
estrogen has no effect on 3T3 cells (Fig. 5B). In contrast, the
activation of BXB-ER and thus ERK1/2 in 3T3BX-BER cells by
estrogen leads to a massive increase of cells in G1-phase of the cell
cycle and to a massive reduction of cells in S-phase, while there is a
Figure 2. BXB-ER activation induces changes in H3K9Me3/HP1 distribution between chromocentres and nucleoplasm and spreads
H3K9Me3 to telomeres. (A) Optical sections of cells that were immunoprocessed for both H3K9Me3 (red in double stains) and HP1b (green in
double stains) as indicated above the panels [77]. The staining pattern reveal the spreading of H3K9Me3 and HP1b to numerous nucleoplasmic sites
upon BXB-ER activation. Normal chromocentres with co-localized H3K9Me3/HP1b appear yellow (arrowheads) and chromocentres with reduced
HP1H appear red (arrows). Individual immunoflorescences are shown in grey. Scale bars: 20 mm. (B/C) Proportions of cells with immunofluorescence
restricted to chromocentres versus cells with additional nucleoplasmic signals were scored (223 and 129 cells for HP1b and H3K9Me3, respectively).
(D/E) Metaphase spreads from indicated cells, after growing without or with estrogen (*) for 15 hours, were immunoprocessed for H3K9Me3 (red) and
DNA was counterstained with Sytox (green). Optical slices (D) and corresponding 3D reconstructions (E [38]) show normal pericentric H3K9Me3
staining (arrow) and new distinct, small sites of H3K9Me3 on chromosome arms and telomeres (arrowheads) after activation. Scale bars: 5 mm.
(F) Control experiment to show that estrogen treatment has no influence on the pattern of H3K9Me3 distribution in interphase or mitotic 3T3 cells.
Untreated 3T3 cells or 3T3 cells treated for 15 hours with estrogen (*) were immunoprocessed for H3K9Me3 (red) and DNA was counterstained with
Sytox (green). Optical slices of fields showing metaphase spreads (M) and interphase cells (I) are shown. Scale bars: 10 mm.
doi:10.1371/journal.pone.0013322.g002
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the cell cycle distribution are observed after 8 hours of estrogen
treatment and become even stronger after 24 hours of estrogen
treatment.
It has been reported previously that oncogenes can induce cell
cycle arrest and senescence. In the case of Ras and Raf it has been
shown that this cell cycle arrest can depend on the accumulation of
p21 (Cip1/Waf1) (reviewed in [4,11]). p21 is a key cell cycle
regulator, which inhibits activation of cyclin-CDK2/4 complexes
that are required for cells to pass from G1 to S phase of the cell
cycle [44]. To test if BXB-ER activation induces the accumulation
of p21 in our cellular system, we performed time course
experiments of estrogen treatments followed by Western blots for
p21 in 3T3BXB-ER cells and in control 3T3 cells (Fig. 5C). While
p21 was undetectable in proliferating 3T3 cells with or without
estrogen treatment as expected, the activation of BXB-ER in 3T3
BXB-ER cells resulted in the rapid accumulation of p21 (Fig. 5C).
The progressive increase in p21 abundance in 3T3BXB-ER cells
following estrogen treatment correlated with the accumulation of
cells in the G1-phase (Fig. 5B) as would be expected for a p21
induced cell cycle arrest.
Discussion
This report links Raf/ERK activity to an epigenetic phenotype
defined by the specific redistribution of the heterochromatic
Figure 3. HP1/H3K9Me3 interaction is unaffected by HP1 phosphorylation following BXB-ER activation. (A) Western blot for HP1b of
untreated and 15 hours estrogen treated (*) 3T3BXB-ER cells. Lysates in the ‘‘H3K9Me3 IP’’ (right hand) panel were immunoprecipitated using an
antibody specific for H3K9Me3 and Western blotted for HP1b. (B) Autoradiograph of ultra high resolution 2D SDS PAGE gels (pH 4.5–5.5, region
shown around pH 4.9, MWr ,22 kD) of lysates from cells labeled metabolically with
32P [35]. Cells were either untreated, activated with estrogen for
20 min (*) or activated and treated with PD98059 at the same time (* + inhibitor). The spot in the middle of the panels showed reproducible changes
in phosphorylation intensity in 3 experiments, the one shown is a representative. Bars show relative intensities of the phosphorylation intensity of this
spot, relative to all spots on the gel. This spot was later identified as HP1a (see C/D). (C/D) Spots shown in (B) were identified by Peptide Mass
Fingerprinting. For this the spots were cut out from the gel, digested with trypsin and processed for identification by MALDI ToF-MS [35]. Panel C
shows the raw data from the MALDI ToF MS. Peaks were manually picked and submitted to a MASCOT (Matrix Science, UK) search of the non-
redundant MSDB database. (D) Murine HP1a was identified as the best match to the sequences in the database with a MASCOT score of 91 (scores
.70 denoted statistical significance at the 0.05% level). Mass accuracy was set to 100 ppm and three missed tryptic cleavages were allowed, as HP1a
contains a higher than normal amount of Arg (R) and Lys (K). Panel D also shows the 59% sequence coverage of the matching peptides in red.
Sequence coverage went down to 46% with more typical setting of one missed tryptic cleavage allowed (not shown). (E) Western blot for HP1b from
high resolution 2D SDS PAGE gels (pH 3–5.6, region shown around pH 3.8, apparent MW ,22 kDa). The spots shown are the only signals generated
from a much larger Western blot. Spot 1 is the least acidic spot recognized by the HP1b antibody, with the smallest apparent MW. The unnumbered
spot is an artifacts, unique to this experiment. 5 experiments with similar results were performed.
doi:10.1371/journal.pone.0013322.g003
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in heterochromatin organization are important in the regulation of
cell differentiation, senescence, aging and cellular transformation
and might be instrumental for the function of Raf in these cellular
processes (Fig. 6). Our results indicate that there might be several
levels at which Raf activation influences heterochromatin
components. Next to the stable induction of H3K9Me3, Raf
activation induces some changes in the phosphorylation of the
HP1 isoforms a and b (Figs. 3B/E). While we found a single
phospho-isomer of HP1a, we detected 5 putative phospho-
isoforms of HP1b. HP1a phosphorylation shows a transient
increase after 20 min of BXB-ER activation while the unpho-
sphorylated form of HP1b showed a slight decrease in abundance
after prolonged BXB-ER activation, which implies a higher
proportion of phosphorylation. Such an increase in phosphoryla-
tion is difficult to measure if the phosphorylations are spread over
several phopsho-isoforms (Fig. 3E). This differential behavior of
HP1a and HP1b might be a reflection of the slight differences in
their primary sequence and their localization (reviewed in [26]).
Further studies will have to show how Raf activation can change
HP1 phosphorylation (neither HP1a nor HP1b carry any
consensus sites for ERK phosphorylation) and what the functional
consequences of these HP1 phosphorylations might be.
The BXB-ER induced epigenetic changes also result in modifi-
cations of chromosome structure and compromise the efficacy of
metaphase chromosome formation (Fig. 2D/E). Enhanced forma-
tion of heterochromatin, like the one observed after induction of
BXB-ER, is believed to compromise the efficacy of cell cycle
progression,contributingtosenescence[45].Moreover,theobserved
changes also correlate with an altered cell cycle distribution, which is
consistent with cycle arrest occurring within hours of BXB-ER
activation (Fig. 5A/B). These observations are consistent with BXB-
ER activation resulting in the induction of cellular senescence [46–
49]. Alternative pathways of Raf induced senescence are known to
involve p16
INK4A/p14
ARF or p53 induced p21 (Cip1/Waf1) [47].
However, as the NIH 3T3 cells and their derivatives used in this
study areknown tohave lostthe ink4locus[50,51], itis not surprising
that p21 (Cip1/Waf1) accumulation is indeed induced after
activation of BXB-ER (Fig. 5C), under conditions where a profound
G1-phase arrest is observed (Fig. 5A/B).
H3K9Me containing senescence associated heterochromatin
foci (SAHF) are a hallmark for oncogene induced senescence [45].
30–40 SAHF are typically seen in the nuclei of senescent cells,
where individual foci correspond to the condensed chromatin of
single chromosomes. Interestingly, telomeric and centromeric
chromatin domains make little contribution to the structure of
SAHF. This applies to senescence induced by activated Ras, MEK
or other oncogenes [52–54]. In contrast, the morphology of
heterochromatin in interphase after BXB-ER activation is very
different from the well-characterized SAHF phenotypes (e.g
compare. Fig. 1B and [53]). Indeed the epigenetic phenotype we
observe after BXB-ER activation is characterized by telomeres
with strong H3K9Me3 staining (Fig. 2D/E). We thus conclude
that prolonged activation of BXB-ER does not induce typical
senescence, as defined by the formation of SAHF, but a different
epigenetic phenotype.
Notably, the increased expression of p21 that is seen following
prolonged BXB-ER activation is consistent with cell cycle arrest
and the onset of senescence, even though the epigenetic phenotype
we observe is not typical of that seen during the classical forms of
oncogene induced senescence. In future studies it will be
interesting to establish if both states are induced using the p53/
pRB pathway as previously characterized [49,54] and how p21
induction and the epigenetic changes induced by BXB-ER are
connected. Interestingly, in fibroblasts, p21 accumulation can be
induced by post-translational mechanisms [55] as well as by
dysfunctional telomeres [56]. As BXB-ER induces strong
H3K9Me3 at telomeres and this might interfere with telomeric
function, our results are compatible with several alternative
mechanisms by which p21 levels could be regulated [44].
The acquisition of robust pericentric-like markers at telomeres
after prolonged BXB-ER activation might be expected to interfere
negatively with telomere maintenance [57–59] and enhance
telomere shortening [60]. This in turn points towards a potential
role for prolonged Raf activation on cell proliferation capacity in
tumorigenesis [61,62], a process in which Raf is known to be
involved [63–66]. Moreover, inhibition of telomerase function
could counteract the effect of cell transformation and explain the
negative effects of activated Raf, which are seen in a variety of
cancer cells [67,68]. This possibility is supported by the properties
of tumours with mutationally activated B-Raf [48] and is unlikely
to reflect abnormally high levels of Raf activity [69]. Results
described here are consistent with alterations in telomere function,
providing a potential mechanism by which prolonged Raf
activation is involved in regulation of cell growth and transfor-
mation.
The telomere position effect (TPE) is an important mechanism
for silencing genes adjacent to telomeric regions. As prolonged
BXB-ER activation induces the accumulation of H3K9Me3 in
telomeric regions as well as in other distinct regions throughout the
genome (Fig. 2D/E) and since H3K9Me3 is an epigenetic marker
involved in silencing transcription [19,26,31,70] our experiments
point to the possibility that Raf-induced epigenetic changes might
contribute to gene silencing via TPE. While telomere dysfunction
is linked to genomic instability and cancer progression [57,71],
enhanced H3K9Me3 and telomere shortening are essential during
differentiation [72–74]. Prolonged Raf activation is involved in
differentiation, for which nuclear targets are essential and ERK
translocation to the nucleus is a necessity for differentiation
[10,12]. However, our results are consistent with the possibility
that changes in the structure of sub-telomeric chromatin lead to
alterations in telomere function, which contribute to Raf/ERK
induced differentiation (Fig. 6).
At the moment we can only speculate about the possible
biological consequences of the BXB-ER induced changes in
heterochromatin and alterations of chromosome structure de-
scribed in this report (Fig. 6). However, based on our observations,
we suggest that future studies of Raf/ERK function should
evaluate how global changes in the organization of post-
translational chromatin modifications link the signaling pathway
to mechanisms that control down-stream patterns of gene
expression.
Figure 4. Epigenetic changes induced by BXB-ER activation are irreversible. 3T3BXB-ER cells were activated for 15 hours with estrogen,
incubated with MEK inhibitor PD98059 or washed 36 and incubated with fresh medium or fresh medium with PD98059, as shown (left). Black
arrowheads on the labeling schema indicate the time-point at which the cells were immunoprocessed (red) to reveal the distribution of HP1b (A) or
H3K9Me3 (B–E). DNA was counterstained with Sytox (green). Analysis of single optical sections (A–E) shows that H3K9Me3 spreading is not reversible
by chase with fresh medium (D) or PD98059 (E) for 7 hours. The last panel in (A) shows the H3K9Me3 signal of a typical metaphase spread from the
same sample. Scale bars: 5 mm in (A), 10 mm in (B–E).
doi:10.1371/journal.pone.0013322.g004
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Cell culture, constructs, fresh weight determination and
32P labeling
NIH 3T3 cells and 3T3BXB-ER cells were grown at 37uCi na n
incubator with 5% CO2 in DMEM (high Glucose) with 10% FCS.
3T3BXB-ER cells are a mixture of 5 clones derived from NIH
3T3 cells after stable transfection with a BXB-ER producing
construct [35]. BXB-ER is a fusion protein containing the kinase
domain of C-Raf, which is only active in the presence of estrogen
and is described in reference [35]. All activations of BXB-ER were
performed at a final concentration of 5 mM estrogen. All control
cells were treated with 0.1% ethanol (carrier). Where indicated,
cells were treated with 50 mM PD98059 or carrier alone (0.1%
Me2SO) or 20 mM UO-126 or carrier alone (0.2% Me2SO). For
the determination of the fresh weight of cells, 1610
7 cells for each
condition were scraped from cell culture dishes and their weight
determined after pelleting at 1 5006g for 10 min. 4 independent
experiments were performed. For in vivo labeling with
32P, cells
were washed 36 with phosphate free medium and labeled with
carrier free
32P-orthophsophate exactly as described before [35].
Immunofluorescence, confocal microscopy and FACS
analysis
Cells were grown on coverslips and fixed in PBS-PFA
(Phosphate Buffered Saline-Paraformaldehyde) (5 min at 20uC),
Figure 5. Cell cycle distribution of 3T3 and 3T3BXB-ER cells after prolonged activation of BXB-ER and BXB-ER induced
accumulation of p21. (A) Cell cycle analysis of 3T3 and 3T3BXB-ER cells. Exponentially growing cells were left untreated (first panel) or activated
with estrogen for 8 or 24 hours. Cells are gated into different cell cycle stages (as outlined in the figure) dependent on their total DNA content
(Propidium Iodide intensity, F1 abscissa, ranging from 2N for cells in G1-phase to 4N for cells in G2-phase) and the amount of BrdU incorporated into
the genomic DNA in the last 3 h before processing (ordinate, BRDU, low BRDU intensity for cells in G1- and G2-phase, high BRDU intensity for S-phase
cells). (B) shows the numerical analysis of the FACS results - percentages are shown as percent of all gated cells. (C) Western blot for p21.
Exponentially growing 3T3 and 3T3BXB-ER cells were left untreated or incubated for the indicated times with estrogen and blots were processed in
parallel. 20 mg of protein from the various whole cell lysates were loaded into each lane. The parts of the blots where p21 migrates are shown.
doi:10.1371/journal.pone.0013322.g005
Figure 6. Proposed crosstalk between elevated Raf activity and genome heterochromatinization. 1- Prolonged activation of the Raf
pathway (right) triggers nuclear rearrangements compared to cells with normal Raf activity (left). Following Raf activation, chromatin is condensed
and folded into a smaller nuclear volume than in normal cells. At the same time, BXB-ER-induced microtubule bundling in the cytoplasm [35] might
be involved in generating additional physical constraints, which correlate with reduced nuclear volume. 2- Irreversible spreading of heterochromatin
marks (shown in red) might cause a progressive genome silencing, a mechanism that is linked to differentiation or growth inhibition. 3- Such BXB-ER
induced epigenetic remodeling of chromatin occurs both, at sub-telomeric and at dispersed sites throughout the genome. We propose that this
epigenetic switch is part of a mechanism that controls changes in transcription during cell cycle arrest.
doi:10.1371/journal.pone.0013322.g006
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before blocking in PBS-BSA (2%) for 60 min. Primary antibodies
against HP1b (Euromedex, 1:400) and fibrillarin (Abcam, 1:400)
were diluted in PBS-BSA (Bovine Serum albumin) (2%) and
incubated at 4uC overnight. After 3 washes in PBS-Tween
(0.02%), the coverslips were incubated with secondary antibodies
coupled to Cy3 (Jackson ImmunoResearch 1:300,) or Alexa Fluor
488 (Molecular Probes 1:500) for 1 hour at 20uC in the dark. After
3 washes in PBS-Tween (0.02%) the samples were briefly post-
fixed in PBS-PFA 1%. Counterstaining of DNA was performed
with 0.25 mM Sytox green (Invitrogen) and samples were finally
mounted with Vectashield (Vector Laboratories). A confocal
microscope (Zeiss LSM510, with a plan apochromat 636
objective, DIC 1.4NA) was use to capture single optical sections.
For 3D views, slides with tape spacers, to avoid cell/nucleus
squashing, were used to mount the coverslips. The basis for the
reconstructions were 300 nm z-stepped stacks, which were
combined using Zeiss and Imaris software. For phenotype
quantification and the measurement of nuclear diameters random
field single optical slice pictures were taken and cells were put into
bins according to criteria outlined in the text. Specifically, the
staining patterns for H3K9Me3 and HP1b were defined as
follows. The bin ‘‘chromocentres only’’ was defined by the absence
of none-particulate and homogeneous immunofluorescence signal
in the nucleus; i.e. less than 40% of the area of the optical slice of
the nucleus showed a visible signal and more than 80% of this
signal was due to strong granular stains. The bin ‘‘chromocentres
and nucleoplasm’’ was defined by a signal in more than 40% of the
area of the nucleus and more than 20% of the area with a signal
was due to homogeneously stained nucleoplasm as opposed to
strong granular stains.
Cell cycle analysis of 3T3BXB-ER cells was performed
according to [75]. In short, BrdU was added to the medium
4 hours before processing for FACS analysis. Cells were fixed,
membranes permeabilized and samples were then treated with
propidium iodide, before being analyzed on a FACS Calibur
(Becton Dickinson).
2D SDS PAGE Western Blotting and Immunoprecipitation
2D gel electrophoresis was performed as described before [35]
with some modifications. 3610
6 cells in 10 cm culture dishes were
washed twice in ice cold PBS, scraped from the plate with an
eraser and washed once more in 0.56PBS before being lysed in
300 ml sample buffer (11 M urea, 4% CHAPS, 40 mM Tris, 1%
dithioerythritol, 2.5 mM EDTA, 2.5 mM EGTA). DNA was
removed by centrifugation at 100 0006 g (60 min) and the
samples (representing 70–200 mg from 1–3610
6 cells) were loaded
(after adding loading ampholytes pH 3–10, 0.5%, GE Healthcare)
on custom made narrow pH range IPG strips on plastic supports
(see figure legend). After running for 120 kVH in a stepwise
manner the gels were processed as described in [35]. The 2D SDS
PAGE gels were silver stained and dried for exposure to a
PhoshorImager, Typhoon. ImageQuant software was used for
quantification of
32P signals. For Western blots of 2D gels an
8610 cm piece of the 2D gel with the region of interest in the
middle was cut out and processed as described before [38] using
primary antibodies against HP1b (Euromedex, 1:500). Western
blots from SDS PAGE gels were performed as described in [38],
using antibodies against ERK1/2 phosphorylated on residues Thr
202/Tyr 204 (Cell Signaling Technology, 1:1000), ERK (Sigma,
1:10 000), HP1b (Euromedex, 1:500) and p21 (Abcam, 1:100). To
ensure equal protein load from different samples, protein contents
of whole cell lysates were measured by the method of Bradford and
equal protein amounts were loaded. Blots were re-probed after
stripping for 30 min at 50uC in 2% SDS, 50 mM Tris pH 8.8 and
1% b-Mercaptoethanol. Immunoprecipitations were performed
exactly as described before [38] using primary antibodies against
H3K9Me3 (Abcam, 1:50). Immunoprecipitates were separated
and subjected to Western blots in parallel to cellular lysates.
Mass spectrometry
Gel signals from scanned silver stains and
32P signals were
aligned using
14C radioactive ink in the corners of the gel. The
Adobe Photoshop two layers/fade function was used to reveal
phosphoproteins corresponding regions on the silver stain gel
image and spots of interest were labeled for subsequent extraction.
The centre of the spots were cut from the gels and destained [76].
Proteins in the gel pieces were digested with trypsin and analyzed
by MALDI-ToF MS (Matrix Assisted LASER Desorption/
Ionization Time of Flight Mass Spectrometry) as described [76],
using a Bruker Reflex III instrument.
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